Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Nathan K Yee

Jinhua Jeff Song

Chris Hugh Senanayake

Xudong Wei

Suresh R Kapadia

Nizar Haddad

Fabrice Gallou

Zhulin Tan

Bo Qu

Jinghua Xu

Xiao-Jun Wang

Sonia Rodriguez

Li Feng Zhang

Carl Alan Busacca

Wenjun Tang

Nitinchandra D Patel

Yongda Zhang

Jean-Nicolas Desrosiers

Joshua Daniel Sieber

Guisheng Li

Daniel Robert Fandrick

Anjan Saha

Yibo Xu

Jianxiu Liu

Azad Hossain

Jolaine Savoie

Said Saim

Rogelio Perez Frutos

Robert Simpson

Thomas Nicola

Jonathan Timothy Reeves

Juergen Schnaubelt

Frank Roschangar

Joerg Brandenburg

Dirk Kemmer

Dieter Gutheil

Jutta Kroeber

Vittorio Farina

Kai Oliver Donsbach

Heewon Lee

Michael Schul

Robert Hagenkoetter

Soumik Biswas

Kendricks Lao

Hari P R Mangunuru

Hans-Dieter Ecker

Eric Winter

Hari PR Mangunuru

This invention relates to novel phosphorous ligands useful for organic transformations. Methods of making and using the ligands in organic synthesis are described. The invention also relates to processes for preparing the novel ligands.

Chiral dihydrobenzooxaphosphole ligands and synthesis thereof

Chiral dihydrobenzoazaphosphole ligands and synthesis thereof

Phosphine ligands of the formula Ia, IB and mixtures thereof. 

Monophosphorus ligands and their use in cross-coupling reactions

Disclosed is a compound of formula (I) and salts thereof. Also disclosed are methods of making the compound of formula (I) and the use of the compound as an intermediate for making pharmaceutically active compounds such as 11-&#x3b2;-hydroxysteroid hydrogenase type 1 (11-&#x3b2;-HSD1) inhibitors.

Indenopyridine derivatives

Disclosed are methods for the preparation of bromo-substituted quinolines of the formula (I) where R is aryl, heteroaryl, alkyl, alkenyl or alkynyl, which are useful as intermediates in the preparation of agents for the treatment of hepatitis C viral (HCV) infections: Formula (I). 

Process for preparing bromo-substituted quinolines

The invention relates to a series of novel chiral phosphorus ligands of formulae (Ia) and (Ib): wherein R, 1-rR&#x3e;4 and X are as defined herein. The invention also relates to chiral metal complexes prepared with these chiral phosphorus ligands. The chiral metal complexes are useful as catalysts for carrying out asymmetric hydro genation. 

Chiral phosphorus ligands

Disclosed is a process for preparing a macrocyclic compound of the formula (I) wherein a hydroxyl-substituted macrocyclic compound of formula (3) is reacted with a sulfonyl-substituted compound of formula QUIN:  The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.

Process for preparing macrocyclic compounds

Disclosed is a process for preparing substituted anisidines of formula I starting from substituted cyclic hydroxy-ketones II via aromatization through a substituted oxime intermediate IV in which R is C-Calkyl or halogen, and Alk is C-Calkyl. The substituted anisidines of formula I have been found to be useful as intermediates in the preparation of agents for the treatment of hepatitis C viral (HCV) infections. 

Process for preparing substituted anisidines

Intermediates of the formula QUIN: and methods for their preparation are described. The intermediate compounds are useful for preparing active agents for the treatment of hepatitis C virus (HCV) infection.

Disclosed is a multi-step process for preparing a macrocyclic compound of the formula (I): wherein Q is a radical of the following formula: and the other variables are as defined herein. The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.

A process for stereoselective synthesis of compounds of Formula X wherein:

Stereoselective synthesis of certain trifluoromethyl-substituted alcohols

A process for stereoselective synthesis of a compound of Formula (I) wherein R, R, R, R, and Rare as described herein.

A process for removing ruthenium or ruthenium-containing compounds from a reaction mixture comprising a compound of the following formula I in an organic solvent using supercritical fluid processing techniques: wherein R, R, R, D and A are as defined herein. This invention has particular application for removing ruthenium-containing catalyst and ruthenium-containing catalyst by products from reaction mixtures that result from ring-closing olefin metathesis (RCM) reactions.

Removal of ruthenium by-product by supercritical fluid processing

Growing community of inventors

Danbury, CT, United States of America

Nathan K Yee